ProPhase LabsPRPH -4.61% Current Ratio is 0.06 as of Dec. 2025, which is 98% below its 10-year median of 3.15. The stock has 4 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 97.67% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ProPhase Labs's current ratio for the quarter that ended in Dec. 2025 was 0.06.
ProPhase Labs has a current ratio of 0.06. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If ProPhase Labs has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for ProPhase Labs's Current Ratio or its related term are showing as below:
PRPH'
s Current Ratio Range Over the Past 10 Years
Min: 0.06 Med: 3.15 Max: 15.68
Current: 0.06
During the past 13 years, ProPhase Labs's highest Current Ratio was 15.68. The lowest was 0.06. And the median was 3.15.
PRPH's Current Ratio is ranked worse than 97.67% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96
vs PRPH: 0.06
ProPhase Labs (OTCPK:PRPH) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
ProPhase Labs Current Ratio Related Terms
ProPhase Labs Current Ratio Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs NSTM, IDTA, IVRO: Current Ratio Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Current Ratio distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (PRPH) has a Current Ratio of 0.06 as of Dec. 2025. This is 98% below median its historical median of 3.15. Over the past decade, ProPhase Labs' Current Ratio has ranged from 0.06 to 15.68. According to the industry distribution chart, ProPhase Labs ranks #210 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 97.7%.
Is ProPhase Labs' Current Ratio too high?
ProPhase Labs' current Current Ratio of 0.06 is 98% below median its 10-year median of 3.15. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 15.68. The Medical Diagnostics & Research industry median Current Ratio is 1.96. ProPhase Labs' value of 0.06 is 96.9% below this industry median. Based on the distribution chart, ProPhase Labs ranks #210 out of 215 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Current Ratio compare to NSTM and IDTA?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #210 out of 215 companies for Current Ratio. This places ProPhase Labs in the lower half of its industry. The industry median Current Ratio is 1.96. ProPhase Labs' value of 0.06 is 96.9% below this benchmark. Historically, ProPhase Labs' own Current Ratio has ranged from 0.06 to 15.68 over the past decade. While the company's 10-year median is 3.15 vs. the industry median of 1.96, ProPhase Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 1.96, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current Current Ratio of 0.06 is 96.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Current Ratio is 0.06, which is 98% below median its own 10-year median of 3.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.09 — trading 86% below its estimated fair value. The current Current Ratio is 0.06, which is 98% below median its 10-year median of 3.15 and 96.9% below the Medical Diagnostics & Research industry median of 1.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Current Ratio is 0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 